london-GSK PLC and Sanofic SA reported promising trial results for its COVID-19 vaccine, showing that the shot – developed to target the beta strain of the virus – was particularly effective against the Omicron variant.
The two companies said on Friday that in a trial involving 13,000 adults, the vaccine demonstrated 64.7% efficacy against symptomatic COVID-19 and 72% in Omicron-confirmed cases. In people who already had antibodies to the infection, the shot was 75.1% effective against symptomatic infection, increasing to 93.2% in omicron-confirmed cases. The study also found that the vaccine was safe for its participants.